It was a delight to catch up with Professor Xavier Mariette (Université Paris-Saclay and Hôpital Bicêtre, Paris, France) around the phase 2 study investigating subcutaneous belimumab and intravenous rituximab in primary Sjögren’s syndrome.
The abstract ‘SAFETY AND EFFICACY OF SUBCUTANEOUS BELIMUMAB AND INTRAVENOUS RITUXIMAB COMBINATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: A PHASE 2, RANDOMISED, PLACEBO-CONTROLLED 68-WEEK STUDY.’ (OP0135) was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
Questions
- What is the rationale for B-cell depletion using belimumab plus rituximab in people with primary Sjögren’s syndrome? (0:15)
- Could you tell us a little about the Phase 2 study, its clinical endpoints, and how well the endpoints were met? (1:09)
- What will be the next steps in the clinical development of this combination in primary Sjögren’s syndrome? (2:25)
Disclosures: Xavier Mariette discloses honorarium from BMS, GSK, Novartis, Pfizer, Servier, UCB and a research grant from Ose Pharmaceutics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
